Speaker
Summary
Introduction
Intrinsic genetic instability and the heterogeneity of malignant cell populations present significant clinical hurdles in oncology, frequently diminishing the effectiveness of conventional receptor-targeted and antigen-based therapies. To address these challenges, Copper-64 chloride ([⁶⁴Cu]CuCl₂) has emerged as a highly promising theranostic agent. Its unique radiophysical properties offer a dual capability for both diagnostic PET imaging, through its positron (β⁺) emissions, and therapeutic intervention via cytotoxic negative beta particles (β⁻) and Auger electrons, which are particularly potent due to their low energy, high linear energy transfer (LET), and extremely limited tissue penetration (< 1 μm). This makes them highly effective for causing irreversible DNA damage when the radionuclide is precisely targeted to the cell nucleus. ⁶⁴Cu is unique in its ionic form, which allows it to reach the proximity of DNA to induce damage. The biological rationale for its use is based on the altered copper metabolism in tumor cells, where cancer cells exhibit an increased demand for copper to support rapid proliferation and metastasis. This study aims to provide a comprehensive in vitro analysis of the interactions of [⁶⁴Cu]CuCl₂ with human cancer cells to deepen the preclinical understanding of its therapeutic potential.
Description of the Work or Project
The study was conducted using two human tumor cell lines, breast adenocarcinoma (MDA-MB-231) and gastric carcinoma (NCI-N87), and a healthy control line, normal human fetal lung fibroblasts (IMR-90). Cells were exposed to increasing activities of [⁶⁴Cu]CuCl₂ (10, 100, and 250 µCi/mL). Cellular and subcellular uptake, cell viability, and apoptosis induction have been evaluated. Our findings demonstrate a significant differential response between malignant and healthy cells. Tumor cell lines showed significantly higher [⁶⁴Cu]CuCl₂ uptake compared to the healthy IMR-90 controls. The MDA-MB-231 breast cancer line, in particular, exhibited the greatest dose-dependent intracellular uptake, with a marked accumulation of ⁶⁴Cu in the nuclear compartment. Treatment with [⁶⁴Cu]CuCl₂ selectively and effectively induced apoptosis in both cancer cell lines in a dose-dependent manner. After 120 hours at 100 µCi/mL, apoptosis increased by nearly 100% in MDA-MB-231 cells and 58% in NCI-N87 cells, compared to just 15% in the healthy IMR-90 fibroblasts.
Conclusions
This study confirms that [⁶⁴Cu]CuCl₂ exhibits high selectivity for cancer cells, characterized by preferential intracellular uptake, significant nuclear localization, and the effective induction of apoptosis, while having minimal cytotoxic effects on healthy cells. These findings position [⁶⁴Cu]CuCl₂ as a promising theranostic candidate for developing targeted therapeutic strategies in oncology, offering a powerful tool to overcome the challenges posed by tumor heterogeneity.
| Are you interested/eligible for the Young Session? | No, I am not eligible |
|---|
